Prognostic value of serum hormone concentrations in prostatic cancer
Article first published online: 20 JUL 2006
Copyright © 1988 Wiley-Liss, Inc., A Wiley Company
Volume 13, Issue 3, pages 249–256, 1988
How to Cite
Eriksson, A. and Carlström, K. (1988), Prognostic value of serum hormone concentrations in prostatic cancer. Prostate, 13: 249–256. doi: 10.1002/pros.2990130307
- Issue published online: 20 JUL 2006
- Article first published online: 20 JUL 2006
- Manuscript Accepted: 15 AUG 1988
- Manuscript Received: 11 JUL 1988
- Maud och Birger Gustavssons stiftelse, Riksföreningen mot cancer
- Karolinska Institutets fonder
- Research Center, Huddinge University Hospital
- serum hormones;
- adrenal androgens;
- therapy response
Seventy-eight patients with cytologically and/or histologically confirmed prostatic cancer were randomly allocated to orchidectomy (ORX, n = 37) or combined intramuscular and oral estrogen treatment (ESTR, n = 41). Serum levels of testosterone (T), 17α- hydroxyprogesterone, dehydroepiandrosterone, dehydroepiandrosterone sulfate, total estrone (tEl;sum of unconjugated and conjugated estrone, ≥85% estrone sulfate), cortisol, luteinizing hormone, follicle-stimulating hormone, prolactin, growth hormone, sex hormone-binding globulin (SHBG), and albumin were determined prior to treatment and 12, 24, and 36 months after initiation of treatment.
Fifty patients responded to treatment or had stable disease, and 28 did not respond (12 in the ORX and 16 in the ESTR group). There was no association between pretreatment hormone or protein levels and outcome of the treatment, neither in the total material nor within either of the two treatment subgroups. Significantly higher pretreatment levels of cortisol and prolactin and significantly lower levels of T, tEl, and albumin and a significantly lower T/SHBG-ratio (index on biologically active T) were found in patients with metastatic disease, compared with the patients without metastases. There was no association between testicular or adrenal androgens, SHBG, T/SHBG, and albumin values during treatment and the clinical outcome.
The differences found between metastatic and nonmetastatic disease probably simply reflect the more stressful and catabolic condition and generally poorer health in patients with disseminated malignant disease. Furthermore, the study does not lend any support to the hypothesis that indicates an important role of adrenal “rest androgen” in prostatic cancer tumor growth.